Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (OADs) for the last 3 months~* HbA1c: 7.0-11.0% (both incl.) for subjects on OAD alone~* HbA1c: 7.0-10.0 % (both incl.) for subjects on OAD combination therapy~* BMI less than 45.0 kg/m\^2~Exclusion Criteria:~* Treatment with insulin within the last 3 months prior to the trial~* Impaired liver or/and renal function~* Significant cardiovascular disease over the last 6 months~* Known retinopathy or maculopathy~* Recurrent major hypoglycaemia or hypoglycaemic unawareness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lira 0.6 + Met (Type: EXPERIMENTAL): Liraglutide 0.6 mg + metformin + glimepiride placebo
- Lira 1.2 + Met (Type: EXPERIMENTAL): Liraglutide 1.2 mg + metformin + glimepiride placebo
- Lira 1.8 + Met (Type: EXPERIMENTAL): Liraglutide + metformin + glimepiride placebo
- Glim + Met (Type: EXPERIMENTAL): Glimepiride 4.0 mg + metformin + liraglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).